New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate.
Ankylosing spondylitis (AS) is the most common of a group of diseases called seronegative spondyloarthropathies. This group of diseases shares common demographic, clinical, and genetic features. This article reviews the rationale, clinical efficacy, and safety reports of etanercept, thalidomide, and pamidronate in the treatment of patients who have AS.
Davis
John C
JC
Division of Rheumatology, Department of Medicine, University of California-San Francisco, 533 Parnassus Avenue, Box 0633, San Francisco, CA 94143, USA. jdavis@medicine.ucsf.edu
Huang
Feng
F
Maksymowych
Walter
W
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000077268:Pamidronate; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D004164:Diphosphonates; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D013792:Thalidomide; D000068800:Etanercept; D000077268:Pamidronate